Fatty Liver Alliance’s Post

Curious about advancements in Alzheimer’s research? Professor Ted Huey, director of the Memory and Aging Program at Butler Hospital, sat down with Providence Business News to discuss the latest developments in memory care. From the FDA approval of donanemab to Butler’s role in groundbreaking clinical trials, this conversation offers a deep dive into how we're working to slow memory decline and improve lives. Catch all the details from Dr. Huey’s insightful interview:

📈 LiverPRO shows an 86% prognostic accuracy validated in +450,000 individuals We are happy to share that we will present our prognostic results on LiverPRO at the EASL Congress 2024. Come by our poster: “LiverPRO outperforms FIB-4 at predicting liver-related events in a cohort of 457.152 individuals” … and lets have a discussion around the benefits and need for early detection and accurate prognosis of at-risk patients. In our study, we compared the effectiveness of LiverPRO and FIB-4 in predicting liver-related events – showing an 86 % prognostic accuracy of LiverPRO. The research is based on the UK Biobank dataset with 457.152 individuals – a general UK patient population aged 40-69. Visit our poster (#FRI-045) on June 7th at the EASL Congress 2024 to explore our results in detail. Want to know more or chat about the findings? Reach out to our CSO Katrine Prier Lindvig! Co-authored by: Katrine Prier Lindvig P Lindvig, Sören Möller, Katrine H Thorhauge, Johanne K Hansen, Camilla D Hansen, Stine Johansen, Helle L Schnefeld, Mads Israelsen, Peter Andersen, Ida Villesen, Katrine T Bech, Nikolaj Torp, Aleksander Krag, Maja Thiele. Check out our other poster for EASL: https://lnkd.in/d5vke6aQ   #EASLCongress2024 #EASLposter #datadrivendiagnostics #steatoticliverdisease

The Evidinno team is gearing up to participate at ISPOR—The Professional Society for Health Economics and Outcomes Research, taking place in Atlanta, GA in early May. Our team will have a total of 4 presentations (3 posters and 1 podium). These achievements stem from our close collaborations with esteemed industry partners and academic experts. Join us at booth 537 to learn more about our company, our recently updated service offerings, and to discover how we can assist you with your research pursuits. We look forward to connecting in-person. Podium Session (P2): Economic Burden and Healthcare Resource Utilization in Sjögren's Disease: A Systematic Literature Review EE74: Economic Burden and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus (SLE): A Systematic Literature Review (SLR) EE176: Economic Burden and Healthcare Resource Utilization in Patients with Psoriatic Arthritis (PsA): A Systematic Literature Review. CO153: Predicting Overall Survival (OS) Benefit in Previously Untreated Metastatic Melanoma from Improvements in Response Outcomes: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs) Save the date: May 5-8! #ISPORAnnual

With only 4 weeks left till the ATMP world tour 2024....let's start meeting our speaker/host pairs! Join Megan Munsie and Oskar Ahlberg for a dive into the interplay between science and society. How do we communicate about our research and what implications can this have for the public and patients? How do we build dialogue with patient communities to ensure that promising technologies and potentially curative medicines are aligned with patient need, developed with trust, hope and risk in mind and that the chances of patient access through health technology assessments are maximised? How can we understand how a patient or a parent is actually feeling in this dialogue? Just some of the insights that you can expect from this expert duo 😍....put it in the calendar! OBS: The title of this session will change closer to the event https://lnkd.in/ggS_UR6V

The Rare Diseases Series: Interview With Ana Bozas (Part 2) - In the second part of this series, Ana Bozas, PhD, CMPP shares her expertise in medical communications within the rare disease sector. She delves into methodologies for assessing communication impact, strategies for staying updated with research, and the importance of tailoring communication for various stakeholders. Ana Bozas also discusses the challenges of time-sensitive communications and highlights trends and innovations in scientific medical communication. Her collaboration with cross-functional teams exemplifies the necessity of cohesive strategies to meet communication goals. This insightful interview not only underscores the critical role of effective communication in advancing rare disease treatments but also serves as a call to action for professionals aiming to make a difference in this field. For an in-depth understanding of these aspects, read the full article here: https://lnkd.in/dcTsvfcK #MedicalCommunications #RareDiseases #MedicalResearch #EnagoLifeSciences

The 19th European Meeting on Complement in Human Diseases (EMCHD 2024), held in Lübeck, Germany brought together top researchers, clinicians, and industry experts to discuss groundbreaking advancements in complement research and its applications in human diseases. From innovative therapeutic strategies to emerging technologies, the conference showcased the future of complement research. Read more about the key takeaways and exciting developments in our latest blog post. Let’s continue to develop the future of life science together! 🌟 #EMCHD2024 #ComplementResearch #Innovation #complementsystem #ScientificExcellence https://hubs.ly/Q02S74z50

An important element of PRAISE-U is understanding the current practice towards early detection in the various EU member states. With the Barriers to Effective Screening Tool (BEST) study, we got more insights into the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers. Read our publication in the Journal of Personalised Medicine to learn about the outcome of this study: https://lnkd.in/eSS44Myp

✍️ 𝐍𝐞𝐰 𝐀𝐫𝐭𝐢𝐜𝐥𝐞 Unlocking the Future of Clinical Research! 🚀🔬 AIS & F-CRIN lead the way: The French Agency for Health Innovation and the French Clinical Research Infrastructure Network unveil groundbreaking guidelines for new clinical research methodologies. Why it matters? ⏩These innovative approaches enhance traditional RCTs, speeding up healthcare product development, especially in challenging areas like rare diseases and antibiotic resistance. 👉 Dive into the latest findings: https://ow.ly/AhEw50S6Osf #ClinicalResearch #HealthcareInnovation #PatientOutcomes

In an insightful interview, Ana Bozas, PhD, CMPP, discusses the unique challenges and approaches in medical communications for rare diseases. Highlighting the significance of patient identification, education, and adherence to regulatory standards, Bozas shares her experiences in bridging the gap between research and clinical application. This article sheds light on the complexities of advocating for rare diseases and the importance of effective communication strategies in enhancing patient care. For a deeper understanding of the impact and methodologies in the field, explore the full article here. https://lnkd.in/dsUKguM8 #MedicalCommunications #RareDiseases #MedicalResearch #EnagoLifeSciences

In a recent webinar, Sano Senior Programme Manager Hayley Holt, PhD provided a comprehensive overview of Sano's innovative approach to patient finding, starting with the development of a customised patient finding protocol. 🔍 Check out the below for a quick summary and a link to the webinar on-demand.👇 https://lnkd.in/eciDBex9 #PatientRecruitment #ClinicalResearch #ClinicalTrials #PrecisionMedicine